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Abstract
Background: With the availability of new preventive and curative interventions, global malaria control has been
strengthened significantly in recent years. Drugs effective in reducing malaria gametocytaemia might contribute to local
elimination and possible long-term eradication. We here report on the effects of methylene blue (MB)-based malaria
combination therapy on gametocytaemia during a randomised-controlled trial in Burkina Faso.
Methods: An open-label randomised controlled phase II study in 180 children aged 6–10 years with uncomplicated
falciparum malaria was conducted in Nouna, north-western Burkina Faso. Children were randomised to MB–artesunate (AS),
MB–amodiaquine (AQ), and AS-AQ (local standard of care). Overall follow-up was for 28 days, follow-up for gametocytaemia
was for 14 days.
Findings: The treatment groups were similar in baseline characteristics and there was only one loss to follow-up. Compared
to AS-AQ, both MB-containing regimens were associated with significantly reduced gametocyte carrier rates during follow-
up days 3, 7, and 14. This effect was seen both in patients with and without P. falciparum gametocytaemia at baseline.
Interpretation: MB reveals pronounced gametocytocidal activity which appears to act against both existing and developing
P. falciparum gametocytes. MB-based combination therapy thus has the potential to reduce transmission of P. falciparum
malaria in endemic regions, which has important implications for future elimination and eradication strategies.
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Introduction
Malaria remains the most important parasitic disease globally,
and in Sub-Saharan Africa (SSA) in particular [1]. New or
rediscovered interventions such as insecticide-treated mosquito
nets [2], artemisinin-based combination therapy (ACT) [3], and
vaccines [4], together with substantially increased funding are
promising in terms of improved malaria control and possibly,
eradication [5–8]. In fact, as a consequence of a large-scale rollout
of available interventions, major reductions in malaria morbidity
and, partially, child mortality have recently been observed in areas
of Kenya, Tanzania and Ethiopia [9–11].
Gametocytocidal antimalarials, and the artemisinines in partic-
ular, may accelerate such progress in that they reduce post-
treatment transmission [12–14]. Yet, artemisinin derivatives do
not prevent post-treatment transmission completely [15], and in
view of emerging ACT resistance in South-East Asia [16–18],
alternative drugs effective against gametocytes are urgently
needed. Methylene blue (MB), the first synthetic drug ever used
against malaria [19], has received renewed attention in recent
years [20]. MB is a subversive substrate and specific inhibitor of
the P. falciparum disulfide reductases and in addition inhibits the
parasite’s heme detoxification [20,21]. MB in combination with a
number of partner drugs has been shown to be safe and effective in
a West-African population with a high prevalence of glucose-6-
phosphate dehydrogenase deficiency [22–25]. Interestingly, plas-
moquine, an antimalarial drug developed as a derivative MB, is
known to be highly effective against gametocytes [26]. In this
context it is also worth mentioning that genes encoding the
putative target proteins of MB [20,21] were present in the
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Kaslow’s laboratory (27). Against this background, we analysed
the efficacy of MB-based combination therapy against gameto-
cytes using data from a randomised controlled phase II study in
Burkina Faso.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
The study was conducted in October/November 2006 in the
urban research zone of the Centre de Recherche en Sante ´ de Nouna
(CRSN) in Nouna Health District, north-western Burkina Faso.
The area is highly endemic for malaria with most clinical cases
occurring during or briefly after the rainy season which lasts from
June until October [27]. Despite an ACT policy since 2005,
malaria control in the study area continues to be mainly based on
home treatment with chloroquine (CQ) [28,29].
Study design and objectives
The study was an open label randomized controlled phase II
trial on safety and efficacy of MB-artesunate (AS) and MB-
amodiaquine (AQ) in children with uncomplicated falciparum
malaria, with blinding only for the laboratory technicians involved.
The primary objective was to investigate the safety of the
combinations MB-AS and MB-AQ in children with uncomplicat-
ed falciparum malaria. The secondary objective was to determine
the efficacy of these MB-based combinations in the treatment of
children with uncomplicated falciparum malaria. The study was
designed to have a statistical power of 80% in order to detect a
difference in the number of adverse events of at least 20% among
study groups that was significant at the five percent level [25].
Post-treatment gametocyte carriage was initially not planned to
examine and specified later as an additional secondary endpoint.
The methodology of the trial has been published elsewhere [25],
and only key aspects are briefly repeated here.
Study population and procedures
Only children from Nouna town were participating in this
study. Inclusion criteria were: age 6–10 years, ability to swallow
tablets, uncomplicated falciparum malaria (axillary temperature
$37.5uC and $1,000 P. falciparum asexual parasites per mL blood),
and written informed consent given by the parents/caretakers.
Exclusion criteria were signs of severe malaria, any apparent other
disease, and malaria treatment – except CQ – with western drugs
and/or antibiotics with antimalarial potency during the preceding
week.
180 children were randomly assigned to receive directly
observed treatment with either MB-AS, MB-AQ, or AS-AQ.
The latter is the official first-line antimalarial in Burkina Faso. MB
(Urolene BlueH, Star Pharmaceuticals, USA) was given at a dose of
10 mg per kilogram of body weight twice daily over three days, AS
(Artesunate, Guilin Pharmaceuticals Co., Ltd., PR China) at a
dose of 4 mg per kilogram of body weight once daily over three
days, and AQ (Essential Drug Store, Ministry of Health, Burkina
Faso) at a dose of 10 mg per kilogram of body weight once daily
over three days. Children with fever $38.5uC received a standard
dose of 10 mg per kilogram paracetamol tablets every 6 hours
(Essential Drug Store, Ministry of Health, Burkina Faso) until
symptoms subsided.
Follow-up of study children was for 28 days using a slightly
modified version of the latest WHO protocol on antimalarial drug
efficacy testing [30]. Children were followed up on days 1, 2, 3, 7,
14, and 28. Mothers and caretakers were encouraged to come
back at any time between scheduled visits in case of unforeseen
symptoms.
A finger-prick blood sample was taken on days 0, 2, 3, 7, 14,
and 28, and during unscheduled visits. From this, malaria
parasitaemia and haematocrit values were determined using
standard CRSN procedures [31]. Filter paper blood samples
served as DNA source for PCR-based differentiation of recrudes-
cences from reinfections [25]. Thick and thin blood films were
examined by two experienced laboratory technicians supervised by
one of the investigators (BC). Asexual parasites (and later
gametocytes during slide re-examination) were counted on thick
blood films against 200 white blood cells (WBCs) and parasite
density was calculated assuming an average WBC count of
10,000/mL. Slides were declared negative if no parasites were seen
in 400 fields on the thick film. For quality control, a 10% random
sample of blood films is regularly cross-checked at the Heidelberg
School of Tropical Medicine, which has always demonstrated an
overall high consistency between the different laboratory techni-
cians with regard to parasite prevalence and density [28]. After
initial reading, all study slides were stored under controlled
conditions in the laboratory of the CRSN.
In early 2008, all slides from the trial (only day 0 until day 14)
were systematically re-examined by two experienced laboratory
technicians supervised by one of the investigators (BC) for P.
falciparum gametocytaemia prevalence and density, both in patients
with ACPR and in patients without ACPR. In view of the short
half-life of both AS and MB, these drugs would have no effect on
new infections emerging after day 14. Thus, gametocytaemia
occurring after day 14 was not considered.
Statistical analysis
The effects of different treatment arms on gametocytaemia were
determined using per protocol analysis. The Chi square test (Chi)
was used to compare proportions, and the non-parametric
Wilcoxon-Mann-Whitney test (WMW) to compare metric or
ordinal data. In order to use the closed testing procedure for
multiple testing adjustment when comparing three groups, a global
test is needed which compares three groups for differences. This is
done by an exact chisquare test which is also valid for small sample
sizes. When possible, estimates and the corresponding 95%
confidence interval are given. Calculations were performed with
the program SAS release 9.1 (SASH Institute Inc, Cary, NC,
USA). Multiple testing between single arms in a three-armed trial
is handeled by the closed testing procedure: If a difference between
all three arms is assessed by a global test on significance level 5%,
it is possible to use the same level for the three two group
comparisons. This procedure keeps the family wise error rate.
Ethical aspects
The study protocol was approved by the Ethics Committee of
the Medical Faculty at Heidelberg University and the local Ethics
Committee of Burkina Faso.
Results
One hundred and eighty children (61 MB-AS, 58 MB-AQ, 61
AS-AQ) were included in the study (Figure 1). There was only one
loss to follow-up. Patients’ demographical, clinical and parasito-
logical characteristics at baseline did not differ between study
groups, except for a small difference in weight (p=0.039; Table 1).
In particular, CQ pre-treatment, parasite density, and gametocyte
carrier rate did not differ significantly between the treatment
groups, although the latter tended to be increased in children
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been published elsewhere. Briefly, PCR-corrected rates of
adequate clinical and parasitological response at day 28 of
follow-up were 62% for MB-AS, 82% for AS-AQ and 95% for
MB-AQ [25].
The prevalence of gametocytes declined following treatment,
regardless of the drug administered. However, both MB-AS and
MB-AQ were significantly more effective in this regard than AS-
AQ during follow-up (Table 2). No gametoctyes were detected one
or two weeks following treatment with the MB-containing regimes
whereas their respective prevalences were 18% and 7% in AS-AQ
treated children.
Similar findings were observed among patients who exhibited
gametocytaemia at enrolment (Table 3).
Excluding patients with P. falciparum gametocytes on day 0 and/
or day 2, both MB-based treatment regimes yielded lower P.
falciparum gametocyte prevalence on day 3 and day 7 compared to
AS-AQ (Table 4). On day 14, no gametocytes were detected in all
study groups.
Discussion
Treatment of malaria with MB-based regimens not only is more
effective than AQ-AS in this part of Burkina Faso [25] but also
associated with a markedly reduced prevalence of P. falciparum
gametocytaemia following treatment. In this first respective study,
the gametocytocidal effect of MB-combination treatment signifi-
cantly exceeded that of AQ-AS. In fact, when following only those
subjects who had gametocytaemia at baseline, P. falciparum
gametocytes were detected exclusively in the ACT control group.
In children presenting without gametocytes, the finding of a lower
P. falciparum gametocytaemia during follow-up in both MB-based
combinations remained but was no longer that marked. These
results point to a broad activity of MB against both, already
Figure 1. Flow chart of study patients.
doi:10.1371/journal.pone.0005318.g001
Table 1. Characteristics of study children at enrolment.
Characteristic MB-AS group (n=61) MB-AQ group (n=58) AS-AQ group (n=61)
Female sex (%) 30 (49) 32 (55) 22 (36)
Median age in years (range) 7 (6–10) 6 (6–10) 7 (6–10)
Median weight in kg (range) 20 (14–32)* 19 (13–38)* 19 (13–33)*
Median haematocrit in % (range) 34 (26–44) 36 (26–42) 34 (24–40)
Median number of P. falciparum trophozoites/ml (range) 33,000 (1,000–265,050) 28,700 (1,000–200,000) 31,000 (1,000–258,000)
Prevalence of P. falciparum gametocytes (%) 9 (15) 7 (12) 15 (25)
Median number of P. falciparum gametocytes/ml (range) 120 (80–160) 200 (40–320) 80 (40–1,280)
Median duration of the current disease episode in days (range) 2 (1–7) 2 (1–7) 2 (1–7)
Reported CQ treatment of current disease episode (%) 6 (10) 12 (21) 10 (16)
*There was a small but significant difference in weight between the study groups (p=0.039).
doi:10.1371/journal.pone.0005318.t001
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However, due to the limited sample size these observations are
based on small and not always statistically significant numbers and
need to be interpreted with some caution. Moreover, P. falciparum
gametocytaemia was not included as a specific endpoint a priori.
This does not change the reliability of our findings as all slides
from the trial were safely stored in the CRSN laboratory and re-
examined by blinded laboratory technicians. Measuring the effects
of the different treatments on submicroscopic gametocytaemia
could have been another option to increase the power of this study.
For instance, in a recent trial in Tanzanian children, gametocytes
were detected in 23% and 89% by microscopy and real-time PCR
assays, respectively [32], and data from The Gambia and Kenya
indicate the transmission potential of submicroscopic gametocy-
taemia [33]. However, standardised collection of appropriate
samples to address this issue was not performed in the present
study.
ACT has been shown to be highly effective against P. falciparum
gametocytes except on the more mature stages of their
development [3,33]. This is supported by our finding of a rather
Table 2. Efficacy of the study regimens against P. falciparum gametocytaemia.
p-values
MB-AS group
N=61
MB-AQ group
N=58
AS-AQ group
N=61 global
MB-AS
vs. MB-AQ
MB-AS
vs. AS-AQ
MB-AQ
vs. AS-AQ
Day 0
- Prevalence (95% CI) 9 (14.8% [7%; 26%]) 7 (12.1% [4%; 20%]) 15 (24.6% [14%; 37%]) 0.168 0.790 0.255 0.100
- Median density (range) 120.0 (80.0–160.0) 200.0 (40.0–320.0) 80.0 (40.0–1280.0)
Day 2
- Prevalence (95% CI) 4 (6.6% [2%; 16%]) 7 (12.1% [5%; 23%]) 9 (14.8% [7%; 26%]) 0.350 0.355 0.240 0.790
- Median density (range) 100.0 (80.0–200.0) 120.0 (80.0–480.0) 160.0 (80.0–1200.0)
Day 3
- Prevalence (95% CI) 2 (3.3%, [1%; 11%]) 0 [0%; 6%] 9 (14.8% [7%; 26%]) 0.002 0.496 0.054 0.003
- Median density (range) 80.0 (40.0–120.0) 160.0 (40.0–440.0)
Day 7
- Prevalence (95% CI) 0 [0%; 6%] 0 [0%; 6%] 11 (18.0% [9%; 30%]) ,.001 ,.001 ,.001
- Median density (range) 120.0 (80.0–480.0)
- missing* 1 1 0
Day 14
- Prevalence (95% CI) 0 [0%; 6%] 0 [0%; 6%] 4 (6.8% [2%; 16%]) 0.035 0.119 0.110
- Median density (range) 180.0 (160.0–400.0)
- missing* 3 1 2
*Patients not available for blood test on respective study days.
doi:10.1371/journal.pone.0005318.t002
Table 3. P. falciparum gametocytaemia during follow-up in patients with P. falciparum gametocytaemia on day 0.
p-values
MB-AS group N=9 MB-AQ group N=7 AS-AQ group N=15 global
MB-AS
vs. MB-AQ
MB-AS
vs. AS-AQ
MB-AQ
vs. AS-AQ
Day 2
- Prevalence (95% CI) 2 (22.2% [3%; 60%]) 1 (14.3% [1%; 66%]) 8 (53.3% [27%; 79%]) 0.142 1.000 0.210 0.165
- Median density (range) 100.0 (80.0–120.0) 480.0 (480.0–480.0) 220.0 (80.0–1200.0)
Day 3
- Prevalence (95% CI) 0 [0%; 34%] 0 [0%; 41%] 5 (33.3% [12%; 62%]) 0.047 0.118 0.135
- Median density (range) 200.0 (160.0–440.0)
Day 7
- Prevalence (95% CI) 0 [0%; 34%] 0 [0%; 41%] 6 (40.0% [16%; 68%]) 0.024 0.052 0.121
- Median density (range) 300.0 (80.0–480.0)
Day 14
- Prevalence (95% CI) 0 [0%; 34%] 0 [0%; 41%] 4 (26.7% [8%; 55%]) 0.134 0.259 0.263
- Median density (range) 180.0 (160.0–400.0)
doi:10.1371/journal.pone.0005318.t003
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baseline. MB-based combinations not only cleared all pre-
existing gametocytes but appeared to have a stronger effect than
AQ-AS on the emergence of young gametocytes following
treatment. This points to the possibility of a synergistic use of
MB and artemisinin derivatives against gametocytes. Unfortu-
nately, the small sample size of the present study did not allow
probing this hypothesis.
The mechanism by which MB acts against gametocytes is
obscure so far. Rapid elimination of asexual parasites (including
fractions committed to gametocytogenesis) by MB-based combi-
nation treatment may be involved in preventing subsequent
gametocytaemia. However, MB-AQ exhibited superior gameto-
cytocidal effects but slower clearance of asexual parasites as
compared to AQ-AS [25]. Interestingly, the remarkable effect of
low doses of a MB derivative, plasmoquine, on P. falciparum
gametocytes has long been known. In Sudanese children in the
early 1930s, plasmoquine given prophylactically at a dosage of
0.02 mg/kg twice weekly, i.e. at a fraction of the therapeutical
dose, almost completely prevented the occurrence of gametocytes
[34]. Similarly, plasmoquine chemoprophylaxis taken twice a
week yielded a substantial reduction of infected mosquitos in
rubber plantation camps in Liberia in 1931 which was attributed
to the drug’s impact on gametocyte carriage [35]. Eventually, the
potential of plasmoquine to interrupt transmission was recognized
and recommended for this purpose [36]. The successor of
plasmoquine, and structurally closely related, is primaquine.
Primaquine not only is the drug of choice to eliminate hypnozoites
in vivax or ovale malaria. Also, in experimental infections, the
drug distinctly reduced the number of circulating gametocytes and
sterilised those remaining [37]. In a recent trial in Tanzania, single
dose primaquine given on the third day of treatment with
sulfadoxine-pyrimethamine (SP) plus AS reduced gametocyte
carriage by more than 80% as compared to SP-AS alone [32].
However, asexual blood stages of P. falciparum are not affected by
therapeutical doses of primaquine, and a reduced gametocytocidal
activity has been reported from India [38,39]. It might be
premature to consider MB as an alternative to primaquine as an
adjunct to P. falciparum treatment, intended to block post-treatment
transmission. Yet, MB shows promising features in this regard
including strong activity against asexual parasites, developing and
mature gametocytes, as well as synergism with artemisinine
derivatives [25,33]. Possibly, and in analogy to plasmoquine,
MB exerts its gametocytocidal effects at dosages below those used
in treatment which might be beneficial in terms of dosing and
tolerability. Taken together, these features warrant further
investigations of MB as a partner compound in ACT and non-
ACT combinations as well as in blocking transmission. In this
regard, studies on the infectivity of gametocytes from MB-treated
individuals are needed.
In summary, this study provides evidence that suggests a high
efficacy of MB-based combination therapy against P. falciparum
gametocytes. A combination of MB with an artemisinin derivate
may thus maximise the gametocytocidal effects of the latter. These
findings add to already existing in vitro and in vivo evidence of a
synergy between MB and artemisinins [25,40]. If such findings
would be confirmed in larger studies and considering the
impending advent of artemisinin resistance [16–18], including
MB in ACT schemes would be an interesting option to improve
treatment efficacy, prevent the development of resistance, and to
reduce the transmission of (resistant) P. falciparum parasites.
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Table 4. Efficacy of the study drugs against P. falciparum gametocytaemia after exclusion of all cases with gametocytes on day 0
and/or day 2.
p-values
MB-AS group
N=50
MB-AQ group
N=45
AS-AQ group
N=45 global
MB-AS
vs. MB-AQ
MB-AS
vs. AS-AQ
MB-AQ
vs. AS-AQ
Day 3
- Prevalence 1 (2.0% [1%;11%]) 0 [0%; 8%] 4 (8.9% [2%; 21%]) 0.079 1.000 0.186 0.117
- Median density (range) 120.0 (120.0–120.0) 60.0 (40.0–120.0)
Day 7
- Prevalence 0 [0%; 7%] 0 [0%; 8%] 4 (8.9% [2%; 21%]) 0.020 0.049 0.117
- Median density (range) 100.0 (80.0–120.0)
- missing* 1 1 0
Day 14
- Prevalence 0 [0%; 8%] 0 [0%; 8%] 0 [0%; 8%]
- Median density (range)
- missing* 3 1 2
*Patients not available for blood test on respective study days.
doi:10.1371/journal.pone.0005318.t004
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